3 TABLE OF CONTENTS 
1 INVESTIGATOR APPROVAL STATEMENT .. oo 00 oo •••••••••• oo 00 oo •••••••••• oo 00 oo •••••••••• oo 00 oo. 3 
2 PROTOCOL SYNOPSIS ............................................................................................ 4 
3 TABLE OF CONTENTS ........................................................................................... 12 
4 LIST OF ABBREVIATIONS .................................................................................... 15 
5 INTRODUCTION ..................................................................................................... 17 
5.1 Backgrmmd and Rationale ............................................................................... 17 
5.2 Clinical and Nonclinical Experience ................................................................ 18 
5.3 Selection of the Doses Used in the Study ........................................................ 19 
5.4 Sumruy ofPotential Risks and Benefits ........................................................ 19 
5.4.1 Potential Risks Associated with Abiraterone Acetate .......................... 20 
5.4.2 Potential Risks Associated with Corticosteroids (Prednisone and 
Methylprednisolone) ............................................................................. 21 
6 OBJECTIVE ........... ........ .......... .............. ......... ................ ....... .......... .......... ...... ......... 21 
7 STUDY DESIGN ....................................................................................................... 21 
8 PATIENT POPULATION ......................................................................................... 22 
8.1 Selection of Study Population .......................................................................... 22 
8 .1.1 Inclusion Criteria .................................................................................. 22 
8.1.2 Exclusion criteria .................................................................................. 23 
8.1.3 Restrictions ........................................................................................... 25 
8.1.4 Removal of Patients from Therapy or Assessment .............................. 25 
9 STUDY PROCEDURES ........................................................................................... 26 
9.1 Screening (Day -28 to -1) ............... ....... ................. ....... .......... .......... ...... ......... 26 
9 .1.1 Visit 1, Screening ................................................................................. 26 
9.2 Detennination of Patient Eligibility , Randornization ....................................... 27 
9 .2.1 Visit 2, Randornization, Day 1 ............................................................. 27 
9.3 Treatlnent Period .............................................................................................. 28 
9.3.1 Day 8 ..................................................................................................... 28 
9.3.2 Visit3,Day9 ........................................................................................ 28 
9.3.3 Visit4,Day10 ...................................................................................... 29 
9.3.4 Day21 ................................................................................................... 30 
9.3.5 Visit5,Day28 ...................................................................................... 30 
9.4 Extension Period .............................................................................................. 31 
9.4.1 Day 42 ................................................................................................... 31 
9.4.2 Visit 6, Day 56 ...................................................................................... 31 